{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:21:19Z","timestamp":1788304879417,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ6615"],"award-info":[{"award-number":["2024JJ6615"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05168-1","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:37:39Z","timestamp":1772775459000},"page":"12157-12168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024"],"prefix":"10.1007","volume":"399","author":[{"given":"Yuqin","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziye","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risheng","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"5168_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.02.007","author":"I Arana","year":"2025","unstructured":"Arana I, Riew GJ, Rock A, Nambudiri VE, Modi B, Shi CR (2025) Cutaneous toxicities associated with epidermal growth factor receptor and mesenchymal epithelial transition factor dual blockade via bispecific antibody amivantamab. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2025.02.007","journal-title":"J Am Acad Dermatol"},{"key":"5168_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5168_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.12.029","author":"B Besse","year":"2025","unstructured":"Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Bernabe Caro R, Kim DW, Lee JS, Cousin S et al (2025) Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A. J Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2024.12.029","journal-title":"J Thorac Oncol"},{"key":"5168_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40259-022-00556-4","volume":"36","author":"D Brazel","year":"2022","unstructured":"Brazel D, Kroening G, Nagasaka M (2022) Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs 36:717\u2013729. https:\/\/doi.org\/10.1007\/s40259-022-00556-4","journal-title":"BioDrugs"},{"key":"5168_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11523-025-01128-6","volume":"20","author":"D Brazel","year":"2025","unstructured":"Brazel D, Smith J, Ou S-H, Nagasaka M (2025) The user\u2019s guide to amivantamab. Target Oncol 20:235\u2013245. https:\/\/doi.org\/10.1007\/s11523-025-01128-6","journal-title":"Target Oncol"},{"key":"5168_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","volume":"24","author":"BC Cho","year":"2023","unstructured":"Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A (2023) Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer 24:89\u201397. https:\/\/doi.org\/10.1016\/j.cllc.2022.11.004","journal-title":"Clin Lung Cancer"},{"key":"5168_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","volume":"6","author":"G da Cunha Santos","year":"2011","unstructured":"da Cunha Santos G, Shepherd FA, Tsao MS (2011) EGFR mutations and lung cancer. Annu Rev Pathol 6:49\u201369. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130206","journal-title":"Annu Rev Pathol"},{"key":"5168_CR8","doi-asserted-by":"publisher","unstructured":"Cutaneous toxicities with amivantamab for non-small cell lung cancer: A practical guide and best practices. Clinical Journal of Oncology Nursing. 2024. https:\/\/doi.org\/10.1188\/24.CJON.559-566.","DOI":"10.1188\/24.CJON.559-566"},{"key":"5168_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1042\/BST20160132","volume":"45","author":"DM De Silva","year":"2017","unstructured":"De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K, Bottaro DP (2017) Targeting the hepatocyte growth factor\/Met pathway in cancer. Biochem Soc Trans 45:855\u2013870. https:\/\/doi.org\/10.1042\/BST20160132","journal-title":"Biochem Soc Trans"},{"key":"5168_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102671","volume":"124","author":"M Dorta-Suarez","year":"2024","unstructured":"Dorta-Suarez M, de Miguel M, Amor-Carro O, Calderon JM, Gonzalez-Ortega M, Rodriguez-Abreu D (2024) The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: diagnosis and future perspectives. Cancer Treat Rev 124:102671. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102671","journal-title":"Cancer Treat Rev"},{"key":"5168_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5168_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2015.1004969","volume":"2","author":"M Holcmann","year":"2015","unstructured":"Holcmann M, Sibilia M (2015) Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol 2:e1004969. https:\/\/doi.org\/10.1080\/23723556.2015.1004969","journal-title":"Mol Cell Oncol"},{"key":"5168_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","volume":"48","author":"L Huang","year":"2014","unstructured":"Huang L, Guo T, Zalkikar JN, Tiwari RC (2014) A review of statistical methods for safety surveillance. Ther Innov Regul Sci 48:98\u2013108. https:\/\/doi.org\/10.1177\/2168479013514236","journal-title":"Ther Innov Regul Sci"},{"key":"5168_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamaoncol.2015.0702","volume":"1","author":"A Jayaram","year":"2015","unstructured":"Jayaram A, Zafeiriou Z, de Bono JS (2015) Cabozantinib-Getting under the skin of cutaneous toxicity. JAMA Oncol 1:535\u2013536. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0702","journal-title":"JAMA Oncol"},{"key":"5168_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07685-5","volume":"21","author":"N Joly-Tonetti","year":"2021","unstructured":"Joly-Tonetti N, Ondet T, Monshouwer M, Stamatas GN (2021) EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function. BMC Cancer 21:5. https:\/\/doi.org\/10.1186\/s12885-020-07685-5","journal-title":"BMC Cancer"},{"key":"5168_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/LCTT.S181406","volume":"10","author":"S Kate","year":"2019","unstructured":"Kate S, Chougule A, Joshi A, Noronha V, Patil V, Dusane R, Solanki L, Tiwrekar P, Trivedi V, Prabhash K (2019) Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl) 10:1\u201310. https:\/\/doi.org\/10.2147\/LCTT.S181406","journal-title":"Lung Cancer (Auckl)"},{"key":"5168_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax2693","author":"J Klufa","year":"2019","unstructured":"Klufa J, Bauer T, Hanson B, Herbold C, Starkl P, Lichtenberger B, Srutkova D, Schulz D, Vujic I, Mohr T et al (2019) Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aax2693","journal-title":"Sci Transl Med"},{"key":"5168_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jjco\/hyv207","volume":"46","author":"T Kozuki","year":"2016","unstructured":"Kozuki T (2016) Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol 46:291\u2013298. https:\/\/doi.org\/10.1093\/jjco\/hyv207","journal-title":"Jpn J Clin Oncol"},{"key":"5168_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70369","volume":"14","author":"G Liu","year":"2025","unstructured":"Liu G, Nyaw SF, Mok TSK, Curcio H, Cortot AB, Kam TY, Descourt R, Chik YK, Cheema P, Gwinnutt JM et al (2025) Patterns of treatment and real-world outcomes of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib: the EXTRACT study. Cancer Med 14:e70369. https:\/\/doi.org\/10.1002\/cam4.70369","journal-title":"Cancer Med"},{"key":"5168_CR20","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"key":"5168_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/0019-5154.131398","volume":"59","author":"B Madke","year":"2014","unstructured":"Madke B, Gole P, Kumar P, Khopkar U (2014) Dermatological side effects of epidermal growth factor receptor inhibitors: \u201cPRIDE\u201d complex. Indian J Dermatol 59:271\u2013274. https:\/\/doi.org\/10.4103\/0019-5154.131398","journal-title":"Indian J Dermatol"},{"key":"5168_CR22","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","volume":"76","author":"SL Moores","year":"2016","unstructured":"Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ et al (2016) A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res 76:3942\u20133953. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2833","journal-title":"Cancer Res"},{"key":"5168_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114198","volume":"208","author":"V Nikolaou","year":"2024","unstructured":"Nikolaou V, Gerochristou M, Sgontzou T, Silaidi C, Stratigos A (2024) Beneath the surface: novel insights into Amivantamab-induced acneiform rash. Eur J Cancer 208:114198. https:\/\/doi.org\/10.1016\/j.ejca.2024.114198","journal-title":"Eur J Cancer"},{"key":"5168_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/1346-8138.12783","volume":"42","author":"T Nomura","year":"2015","unstructured":"Nomura T, Katoh M, Yamamoto Y, Kabashima K, Miyachi Y (2015) Eosinophilic pustular folliculitis: the transition in sex differences and interracial characteristics between 1965 and 2013. J Dermatol 42:343\u2013352. https:\/\/doi.org\/10.1111\/1346-8138.12783","journal-title":"J Dermatol"},{"key":"5168_CR25","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK et al (2021) Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol 39:3391\u20133402. https:\/\/doi.org\/10.1200\/JCO.21.00662","journal-title":"J Clin Oncol"},{"key":"5168_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62356-w","volume":"14","author":"Y Qi","year":"2024","unstructured":"Qi Y, Li J, Lin S, Wu S, Chai K, Jiang X, Qian J, Jiang C (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for capmatinib. Sci Rep 14:11388. https:\/\/doi.org\/10.1038\/s41598-024-62356-w","journal-title":"Sci Rep"},{"key":"5168_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102105","volume":"90","author":"J Remon","year":"2020","unstructured":"Remon J, Hendriks LEL, Cardona AF, Besse B (2020) EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. Cancer Treat Rev 90:102105. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102105","journal-title":"Cancer Treat Rev"},{"key":"5168_CR28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"5168_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1574886313666181026100000","volume":"14","author":"V Subeesh","year":"2019","unstructured":"Subeesh V, Maheswari E, Singh H, Beulah TE, Swaroop AM (2019) Novel adverse events of iloperidone: a disproportionality analysis in US food and drug administration adverse event reporting system (FAERS) database. Curr Drug Saf 14:21\u201326. https:\/\/doi.org\/10.2174\/1574886313666181026100000","journal-title":"Curr Drug Saf"},{"key":"5168_CR30","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","volume":"34","author":"Y Urata","year":"2016","unstructured":"Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D et al (2016) Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol 34:3248\u20133257. https:\/\/doi.org\/10.1200\/JCO.2015.63.4154","journal-title":"J Clin Oncol"},{"key":"5168_CR31","first-page":"3639","volume":"23","author":"S Yano","year":"2003","unstructured":"Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A, Averbuch S, Wadsworth P (2003) Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23:3639\u20133650","journal-title":"Anticancer Res"},{"key":"5168_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq7074","volume":"16","author":"Q You","year":"2024","unstructured":"You Q, Chen L, Li S, Liu M, Tian M, Cheng Y, Xia L, Li W, Yao Y, Li Y et al (2024) Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans. Sci Transl Med 16:eabq7074. https:\/\/doi.org\/10.1126\/scitranslmed.abq7074","journal-title":"Sci Transl Med"},{"key":"5168_CR33","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","volume":"10","author":"J Yun","year":"2020","unstructured":"Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S et al (2020) Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov 10:1194\u20131209. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0116","journal-title":"Cancer Discov"},{"key":"5168_CR34","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.ajpath.2019.08.002","volume":"189","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Song KY, Giubellino A (2019) The role of MET in melanoma and melanocytic lesions. Am J Pathol 189:2138\u20132148. https:\/\/doi.org\/10.1016\/j.ajpath.2019.08.002","journal-title":"Am J Pathol"},{"key":"5168_CR35","doi-asserted-by":"publisher","unstructured":"Zhou S, Lei L, Jiang L, Fu C, Huang J, Zhang K, Wen Y, Chen J, Zeng Q. Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024. Expert Opin Drug Saf. 2024:1\u20136. https:\/\/doi.org\/10.1080\/14740338.2024.2446432.","DOI":"10.1080\/14740338.2024.2446432"},{"key":"5168_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","volume":"151","author":"RC Zuo","year":"2015","unstructured":"Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW (2015) Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol 151:170\u2013177. https:\/\/doi.org\/10.1001\/jamadermatol.2014.2734","journal-title":"JAMA Dermatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05168-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05168-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05168-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:02:35Z","timestamp":1781553755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05168-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5168"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05168-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available data from the FAERS database, which does not contain individually identifiable information. No ethics committee approval was required for this type of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}